Filing Flows › Real Remax Group (REAX) › Stock forecast & fair value
Real Remax Group (REAX) stock forecast and fair value
Real Remax Group (REAX) trades at $14.97. 6 analysts' median price target is $30.38 (+103%), from $4.00 to $65.00. Across 4 valuation methods the middle fair value is $10.93 (-27%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| Analysts' price targets | $4.00 | $29.21 | $65.00 | +95% |
| Tangible book (asset value) | $8.75 | $10.93 | $10.93 | -27% |
| Net cash (floor) | $0.00 | $0.00 | $0.00 | — |
| Stage-weighted value (pre-revenue) | $3.28 | $4.10 | $4.10 | -73% |
Real Remax Group's latest quarter
Real Remax Group, Q3 2026: revenue $728M (+28% year over year), operating margin -9.9%, net loss $67.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for REAX stock?
The median of 6 analysts' 12-month targets is $30.38, +103% from $14.97; the range is $4.00 to $65.00. The average rating is none.
What is Real Remax Group's fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between $0.00 and $29.21, with a middle value of $10.93 against a price of $14.97. Each method's assumptions are on the page.
Does Real Remax Group usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is REAX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.